Malignant Melanoma
📧 Sign up to get email alerts when something new happens for Malignant Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-05-01Clinical Trial Update: Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery [Phase 2]
This Phase 2 trial evaluated bevacizumab with temozolomide or bevacizumab with nab-paclitaxel and carboplatin in patients with stage IV mali…
-
CLINICAL_TRIALS trial_result · 2018-04-23Clinical Trial Update: CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) [Phase 2]
A Phase 2 trial investigating extended dosing of CAVATAK in patients with advanced melanoma (Stage IIIc/IV) has completed and posted results…
-
CLINICAL_TRIALS trial_result · 2017-12-27Clinical Trial Update: Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma [Phase 2]
Phase 2 clinical study investigating apatinib as second-line therapy for malignant melanoma.
-
CLINICAL_TRIALS trial_result · 2017-12-20Clinical Trial Update: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating fluorescein for lymphatic mapping and sentinel lymph node biopsy in patients with stage I-II malignant…
-
CLINICAL_TRIALS trial_result · 2017-12-18Clinical Trial Update: A Study of Vemurafenib in Participants With Metastatic Melanoma [Phase 3]
Phase 3 trial update for vemurafenib in metastatic melanoma has completed; results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies [Phase 1]
Phase 1 bioavailability study of vemurafenib in participants with BRAF V600 mutation-positive malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2017-10-03Clinical Trial Update: Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma [Phase 1, Phase 2]
Clinical trial update on the combination of Decitabine and Temozolomide in metastatic melanoma (Phase 1/2) with completed status and posted …
-
CLINICAL_TRIALS trial_result · 2017-08-24Clinical Trial Update: Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab [Phase 1]
Phase 1 study evaluating the selective HDAC6 inhibitor ACY-241 in combination with ipilimumab and nivolumab for malignant melanoma has compl…
-
CLINICAL_TRIALS trial_result · 2017-08-22Clinical Trial Update: Safety Study of PLX4032 in Patients With Solid Tumors [Phase 1]
Phase 1 safety study of PLX4032 (vemurafenib) in patients with solid tumors, including malignant melanoma and colorectal cancer; results hav…
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma [Phase 2]
This is a Phase 2 trial evaluating temsirolimus in combination with bevacizumab for stage III/IV malignant melanoma; results have been poste…
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer [Phase 1]
A Phase 1 trial evaluated autologous invariant natural killer (iNKT) cells expanded in vitro for cancer therapy in malignant melanoma and ha…
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E [Phase 2]
Phase 2 study of vemurafenib (Zelboraf) in patients with locally advanced unresectable Stage IIIc or metastatic melanoma carrying activating…
-
CLINICAL_TRIALS trial_result · 2017-05-15Clinical Trial Update: A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) [Phase 2]
Phase 2 study of intratumoral CAVATAK in patients with stage IIIc/IV malignant melanoma has completed; results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-05-03Clinical Trial Update: Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB [Phase 3]
A Phase 3 clinical trial evaluating Pegylated Interferon-alpha-2a in patients with malignant melanoma (Stage IIA-IIIB) has completed.
-
CLINICAL_TRIALS trial_result · 2017-04-21Clinical Trial Update: A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma [Phase 2]
Phase 2 trial evaluating bevacizumab in combination with dacarbazine in unresectable/metastatic melanoma has completed and results have been…
-
CLINICAL_TRIALS trial_result · 2017-04-19Clinical Trial Update: A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma [Phase 2]
Phase II trial evaluating vemurafenib combined with acitretin in advanced melanoma has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2017-03-28Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) [Phase 2]
A Phase 2 trial comparing pembrolizumab to chemotherapy in advanced melanoma has completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) [Phase 3]
Phase 3 trial comparing BMS-936558 (nivolumab) to physician's choice chemotherapy in advanced melanoma after anti-CTLA-4 therapy; trial comp…
-
CLINICAL_TRIALS trial_result · 2017-03-20Clinical Trial Update: A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies [Phase 1]
This Phase 1 trial evaluates the pharmacokinetic interaction between vemurafenib and a single dose of tizanidine in patients with BRAFV600 m…
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer [Phase 2]
A Phase 2 trial evaluating recombinant interleukin-21 (rIL-21) for metastases in lymph nodes due to malignant melanoma. The study has been t…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma [NA]
Completed Phase I trial evaluating intratumoral delivery of an interleukin-12 plasmid (pIL-12) by electroporation in malignant melanoma.
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) [Phase 1]
This Phase 1 pharmacokinetics study evaluated the effect of rifampin on the pharmacokinetics of vemurafenib (Zelboraf) in patients with mali…
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System [Phase 2]
This Phase 2 clinical trial evaluating temozolomide with radiation therapy for stage IV malignant melanoma with measurable and unresectable …
-
CLINICAL_TRIALS trial_result · 2016-11-17Clinical Trial Update: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies [Phase 2, Phase 3]
This clinical trial update reports results from a study of continued treatment with peginterferon alfa-2a or recombinant interferon alfa-2a …
-
CLINICAL_TRIALS trial_result · 2016-11-02Clinical Trial Update: A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma [Phase 1]
Genentech completed a Phase 1 study of the investigational agent DEDN6526A in patients with metastatic or unresectable malignant melanoma. T…